A review of retroperitoneal liposarcoma genomics

Research output: Contribution to journalReview articlepeer-review


  • Robert Tyler
  • Kasun Wanigasooriya
  • Philippe Taniere
  • Max Almond
  • Samuel Ford
  • Anant Desai

Colleges, School and Institutes

External organisations

  • University Hospital Birmingham NHS Foundation Trust


Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their extremity counterparts. Within their subtypes - well differentiated (WDL), dedifferentiated (DDL), myxoid (MLS) and pleomorphic (PLS) - they exhibit a diverse genomic landscape. With recent advances in next generation sequencing, the number of studies exploring this have greatly increased. The recent literature has deepened our understanding of the hallmark MDM2/CDK4 amplification in WDL/DDL and addressed concerns about toxicity and resistance when targeting this. The FUS-DDIT3 fusion gene remains the primary focus of interest in MLS with additional potential targets described. Whole genome sequencing has driven identification of novel genes and pathways implicated in WDL/DDL outside of the classic 12q13-15 amplicon. Due to their rarity; anatomical location and histologic subtype are infrequently mentioned when reporting the results of these studies. Reports can include non-adipogenic or extremity tumours, making it difficult to draw specific retroperitoneal conclusions. This narrative review aims to provide a summary of retroperitoneal liposarcoma genomics and the implications for therapeutic targeting.


Original languageEnglish
Article number102013
JournalCancer Treatment Reviews
Early online date28 Mar 2020
Publication statusPublished - Jun 2020


  • liposarcoma, retroperitoneal, genomics, therapeutics, review